CGTX – cognition therapeutics, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

CGTX

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

3/2

08:01 am

cgtx

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis [Yahoo! Finance]

Low Report

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis [Yahoo! Finance]

Report

3/2

07:30 am

cgtx

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

Low Report

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

Report

2/6

05:33 pm

cgtx

Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.

Low Report

Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.

Report

2/5

07:30 am

cgtx

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Medium Report

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Report

2/5

06:09 am

cgtx

Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.

Medium Report

Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.

Report

1/27

07:30 am

cgtx

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

Medium Report

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

Report

1/6

07:47 am

cgtx

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies [Yahoo! Finance]

Low Report

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies [Yahoo! Finance]

Report

1/6

07:30 am

cgtx

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies

Low Report

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.